Parkinson's disease and dementia with Lewy bodies are currently defined by their clinical
features, with α-synuclein pathology as the gold standard to establish the definitive …

That certain cell types in the central nervous system are more likely to undergo
neurodegeneration in Parkinson's disease is a widely appreciated but poorly understood …

Intracellular α-synuclein (α-syn)-rich protein aggregates called Lewy pathology (LP) and
neuronal death are commonly found in the brains of patients with clinical Parkinson disease …

Parkinson's disease is a progressive neurodegenerative condition associated with the
deposition of aggregated α-synuclein. Insights into the pathogenesis of Parkinson's disease …

Parkinson's disease is a neurological disorder with evolving layers of complexity. It has long
been characterised by the classical motor features of parkinsonism associated with Lewy …

For the last two decades, pathogenic concepts in Parkinson disease (PD) have revolved
around the toxicity and spread of α-synuclein. Thus, α-synuclein would follow caudo-rostral …

This article reviews and summarizes 200 years of Parkinson's disease. It comprises a
relevant history of Dr. James Parkinson's himself and what he described accurately and …

Parkinson disease (PD) treatment options have conventionally focused on dopamine
replacement and provision of symptomatic relief. Current treatments cause undesirable …

Parkinson's disease is a common, progressive neurodegenerative disorder, affecting 3% of
those older than 75 years of age. Clinically, Parkinson's disease (PD) is associated with …

Autosomal-recessive early-onset parkinsonism is clinically and genetically heterogeneous.
The genetic causes of approximately 50% of autosomal-recessive early-onset forms of …